disease – Investorempires.com

Associated Press

Florida’s citrus industry faces threats from hurricanes, disease and real estate

HydroGraph Announces Upsize of Private Placement to $3.2M

ACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing Regimen

HydroGraph Announces Upsize of Private Placement to $3.2M

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

HydroGraph Announces Upsize of Private Placement to $3.2M

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

HydroGraph Announces Upsize of Private Placement to $3.2M

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Teva credit: Cineberg/Shutterstock

Teva jumps sharply on bowel disease drug results

T.J. Maxx parent lifts profit forecast on easing costs, steady demand By Reuters

Sanofi MS drug tolebrutinib misses goal in relapsing disease trials By Reuters

CytoReason cofounder and CEO David Harel credit: Geva Talmor

Israeli AI disease models co CytoReason raises $80m

Greencity Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding the Determination of Delisting

“LEQEMBI” Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Israel By Investing.com

HydroGraph Announces Upsize of Private Placement to $3.2M

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease